Abeona Therapeutics Inc.
5.09
-0.52 (-9.27%)
At close: Jan 14, 2025, 3:59 PM
5.11
0.39%
After-hours Jan 14, 2025, 05:26 PM EST
undefined%
Bid 5.09
Market Cap 221.27M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.05
PE Ratio (ttm) -2.48
Forward PE n/a
Analyst Buy
Ask 5.98
Volume 624,470
Avg. Volume (20D) 253,440
Open 5.66
Previous Close 5.61
Day's Range 5.05 - 5.66
52-Week Range 3.05 - 9.01
Beta undefined

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 19, 1980
Employees 84
Stock Exchange NASDAQ
Ticker Symbol ABEO

Analyst Forecast

According to 3 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 253.63% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Abeona Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025, before market opens.
Analysts project revenue of $83.33K, reflecting a n/a YoY growth and earnings per share of -0.34, making a -46.88% decrease YoY.
5 months ago · Source
+11.99%
Abeona Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
8 months ago · Source
+12.14%
Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.